Christian Rohlff

Dr Rohlff has been CEO of Oxford BioTherapeutics since founding the company and acquiring key technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry. Following his PhD in Pharmacology from Georgetown University, Christian worked at the US National Cancer Institute in Bethesda, Maryland. Prior to founding OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA.